circlepharma.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $208.31MM
Circle Pharma is a biotechnology company which offers macrocycle therapeutics to patients with diseases and cancers. Circle Pharma’s proprietary MXMO™ platform is designed to target intracellular protein-protein interactions (PPIs), combining drug design with synthetic chemistry advancements to create drug candidates that are intended to be cell-permeable and orally bioavailable for oncology treatments. This company was founded by Matthew Jacobson Ph.D and Scott Lokey Ph.D in 2012 and is headquartered in South San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/03/2024 | Series D | $90MM | $xx.xx | $286.88MM | Euclidean Capital, Nextech Invest, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
143,380,596
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Euclidean Capital, Nextech Invest, The Column Group
|
||||||
06/16/2021 | Series C | $66.3MM | $xx.xx | $257.55MM | Berkeley Catalyst Fund, Eli Lilly & Company, Euclidean Capital, Hartford Healthcare Endowment, Lifeforce Capital, Nextech Invest, Pandect Bioventures, Pavillion Capital, Shangpharma Innovation, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
78,005,871
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Berkeley Catalyst Fund, Eli Lilly & Company, Euclidean Capital, Hartford Healthcare Endowment, Lifeforce Capital, Nextech Invest, Pandect Bioventures, Pavillion Capital, Shangpharma Innovation, The Column Group
|
||||||
03/17/2020 | Series B | $45MM | $xx.xx | $92.99MM | Berkeley Catalyst Fund, Lifeforce Capital, Nextech Invest, Pandect Bioventures, Shangpharma Innovation, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
104,651,160
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Berkeley Catalyst Fund, Lifeforce Capital, Nextech Invest, Pandect Bioventures, Shangpharma Innovation, The Column Group
|
||||||
04/25/2017 | Series A | $2.5MM | $xx.xx | $15.56MM | Berkeley Catalyst Fund, Elements Partners, Lifeforce Capital, Mission Bay Capital, Pfizer, Shangpharma Innovation, Whitesun Healthcare Ventures, Wi Harper Group | |
Price per Share
$xx.xx
Shares Outstanding
5,108,742
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Berkeley Catalyst Fund, Elements Partners, Lifeforce Capital, Mission Bay Capital, Pfizer, Shangpharma Innovation, Whitesun Healthcare Ventures, Wi Harper Group
|
||||||
12/21/2016 | Series A-1 | $4.5MM | $xx.xx | $12.86MM | Mission Bay Capital, Pfizer, Shangpharma Innovation | |
Price per Share
$xx.xx
Shares Outstanding
9,183,673
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mission Bay Capital, Pfizer, Shangpharma Innovation
|